Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNAGIS vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Palivizumab is a humanized monoclonal antibody that binds to the A antigenic site of the fusion (F) protein of respiratory syncytial virus (RSV), inhibiting viral entry into host cells by preventing fusion of the viral envelope with the host cell membrane.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Prophylaxis of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients with bronchopulmonary dysplasia (BPD), history of preterm birth (≤35 weeks gestational age), or hemodynamically significant congenital heart disease (CHD)
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg (2 m L) per injection.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
18-27 days (terminal half-life in pediatric patients, mean ~21 days). Allows monthly dosing during RSV season.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Palivizumab is a monoclonal antibody; it is degraded into small peptides and amino acids via catabolic pathways, similar to endogenous Ig G. No specific metabolic enzymes are involved.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Renal: minimal intact Ig G recovered in urine; likely catabolized to peptides/amino acids. Fecal/biliary: not significantly eliminated. Main route: proteolytic catabolism.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
~98-99% bound, primarily to Ig G receptors (Fc Rn) and endogenous Ig G; binding to other serum proteins minimal.
Protein binding is approximately 99.5%, primarily to albumin.
~1.0-1.5 L/kg in infants; reflects distribution primarily within vascular space and extracellular fluid.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
IM: ~80-100% (nearly complete absorption after intramuscular injection).
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
No dose adjustment required for renal impairment.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dose adjustment required for hepatic impairment.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
Infants and children up to 24 months: 15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg per injection.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
Not indicated for use in adults; no geriatric dosing data available.
Not indicated for geriatric population; no dosing recommendations available.
None
No black box warning.
Anaphylaxis and hypersensitivity reactions (rare but severe),Coagulation disorders (thrombocytopenia) with bleeding complications in patients with CHD,Risk of infection transmission if administered with contaminated equipment,Not indicated for treatment of RSV disease,May interfere with RSV diagnostic tests
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
History of severe hypersensitivity reaction to palivizumab or any component of the product
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No known food interactions. Administer without regard to meals.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Palivizumab is a humanized monoclonal antibody (Ig G1) that crosses the placenta, with increasing transfer in the second and third trimesters. No teratogenic effects have been reported. Use only if clearly needed.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
Not known whether palivizumab is excreted in human milk. Ig G antibodies are transferred into milk, but systemic absorption by the infant is minimal. M/P ratio not established. Consider developmental benefits of breastfeeding versus theoretical risk of exposure. Caution advised.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No dosing adjustments required due to pregnancy. Pharmacokinetics of palivizumab are not expected to be significantly altered by pregnancy. Standard dosing: 15 mg/kg intramuscularly once monthly during RSV season.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
Administer intramuscularly only, preferably in the anterolateral thigh; do not use if turbid or discolored; observe for 30 minutes post-injection for hypersensitivity; not for treatment of RSV disease; efficacy unproven in children with congenital heart disease other than hemodynamically significant conditions; may interfere with immune response to live vaccines; palivizumab is a monoclonal antibody, not a vaccine.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
This medication is given as a shot to prevent serious RSV lung infection; it does not treat existing infection.,Your child will receive injections monthly during RSV season (typically November through March).,Common side effects include fever, rash, and injection site reactions like redness or swelling.,Seek medical attention if your child develops signs of allergic reaction: hives, difficulty breathing, swelling of face/lips.,Inform healthcare provider about any bleeding disorders or recent vaccinations before receiving Synagis.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNAGIS vs BEYFORTUS, answered by our medical review team.
SYNAGIS is a Monoclonal Antibody that works by Palivizumab is a humanized monoclonal antibody that binds to the A antigenic site of the fusion (F) protein of respiratory syncytial virus (RSV), inhibiting viral entry into host cells by preventing fusion of the viral envelope with the host cell membrane.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNAGIS and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNAGIS is: 15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg (2 m L) per injection.. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNAGIS and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNAGIS is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Palivizumab is a humanized monoclonal antibody (IgG1) that c. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.